Cytokines and the immune response

Biotherapy

Volumn 8, Issue 3-4, 1996, Pages 243-249

  Van Der Meide, P H ^a,b   Schellekens, H ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETA INTERFERON; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GLYCOPROTEIN GP 120; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; SOLUBLE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; APOPTOSIS; AUTOIMMUNITY; DRUG THERAPY; ETIOLOGY; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INFECTION; MACROPHAGE; MONOCYTE; MYASTHENIA GRAVIS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL LYMPHOCYTE; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ANIMALS; CYTOKINES; HUMANS; IMMUNITY; INFLAMMATION; MICE;

EID: 0029884547     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01877210     Document Type: Review

References (54)

1. Babior BM. Oxidants from phagocytes: agents of defense and destruction. Blood 1984; 64: 959-88.
2. Belosevic M, Finbloom DS, Van der Meide PH, Slayter MV, Nacy CA. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 1989; 143: 266-74.
3. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977-80.
4. Billiau A, Vandckerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 1991; 21: 559-73.
5. Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, Kishimoto T, Martinez-Maza O. Infection with HIV is associated with elevated IL-6 levels. J Immunol 1990; 144: 480-4.
6. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-7 induction by natural kill cell stimulatory factor (NKSF/IL-12): role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992; 148: 92-8.
7. H2 switch is a critical step in the etiology of HFV infection. Immunol Today 1993; 14:107-11.
8. Dalgleish AG, Beverly PCL, Clapman PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763-7.
9. De Waal Malefyt R, Haanen J, Spits H, Roncarolo M-G, Te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, De Vries JE. 11-10 and viral 11-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class IIMHC expression. J Exp Med 1991; 174: 915-24.
10. De Waal Malefyt R, Figdor CG, Huijbers R, Mohan-Peterson S, Bennett B, Culpepper J, Dang W, Zurawski G, De Vries JE. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993; 151:6370-81.
11. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G. Immunopathogenic mechanisms in human Immunodeficiency virus (HIV) Infection. Ann Int Med 1991 ; 114: 678-93.
12. Griffin WST, Stanley LC, Ling C, White L, Macleod V, Perrot LJ, White CL III, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7611-5.
13. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-6.
14. Hartung H-P, Schäfer B, Van der Meide PH, Fierz W, Heininger K, ToykaKV. The role of interferon-gammain thepathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann Neural 1990; 27: 247-57.
15. Häyry P, Ferry B, Leszczynski D, Manca F, Jaakkola M, Halttunen J, Von Willebrand E, Schellekens H, Van der Meide PH. Generation and breakdown of a vicious cycle in context of acute allograft rejection. Transpl Proc 1986; XVIII: 52-62.
16. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 1991; 88:7011-5.
17. Hober D, Haque A, Wattre P, Beaucaire G, Mouton Y, Carpon A. Production of tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) in patients with AIDS. The enhanced level of TNF-α is related to higher cytotoxic activity. Clin Exp Immunol 1989; 78: 329-33.
18. Honda M, Kitamura K, Mizutani Y, Oishi M, Arai M, Okura T, Igarahi K, Yasukawa K, Hirano T, Kishimoto T. Quantitative analysis of serum 11-6 and its correlation with increased levels of serum IL-2R in HFV-induced diseases. J Immunol 1990; 145: 4059-64.
19. Howard MA, O'Garra A, Ishida H, De Waal Malefyt R, De Vries JE. Biological properties of Interleukin 10. J Clin Immunol 1992; 12: 239-47.
20. Howard OMZ, Clouse KA, Smith C, Goodwin RG, Farrar WL. Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation. Proc Natl Acad Sci USA 1993; 90: 2335-9.
21. 1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987; 166: 798-803.
22. Jacob CO, Holoshitz J, Van der Meide PH, Strober S, McDevitt HO. Heterogeneous efects of IFN-gamma in adjuvant arthritis. J Immunol 1989; 142:1500-5.
23. Jacobson SEW, Okkenhaug C, Veiby OP, Caput D, Ferrara P, Minty A. Interleukin 13: novel role in direct regulation of proliferation and differentiation of primitive hematopoietic progenitor cells. J Exp Med 1994; 180: 75-82.
24. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med (1990) 85: 289-91.
25. Lance HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, Walker R, Deyton L, Davey RT Jr, Falloon J. Interferonapha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 805-11.
26. Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walter R, Deyton L, Metcalf JA, Baseler M, Salzman N. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2: 1218-22.
27. Lew W, Oppenheim JJ, Matsushima K. Analysis of the suppression of IL-1 alpha and IL-1 beta production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone. J Immunol 1988; 140: 1895-902.
28. H0 cells. Science 1994; 265: 244-8.
29. Michie HR, Manoque KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello C, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumour necrosis factor after endotoxin administration. NEngl JMed 1988; 318: 1481-6.
30. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature (Lond.) 1993; 362: 248-50.
31. Moore KW, O'Garra AO, De Waal Malefyt R, Vieira P, Mosmann TR. Interleukin 10. Annu Rev Immunol 1993; 11: 165-90.
32. H2 cells: Different patterns of lymphokines secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-73.
33. Nathan CF, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991; 3:65-70.
34. Panitch HS, Hirsch RL, Schindler J, Johnson KP. (1987) Treatment of multiple sclerosis with gamma Interferon: exacerbations associated with activation of the immune system. Neurology 37: 1097-102.
35. Pearce EJ, Caspar P, Grzych J-M, Lewis FA, Sher A. Downregulation of TH 1 cytokine production accompanies induction of TU 2 responses by a parasitic helminth, Schistosoma mansoni. JExp Med 1991; 173: 159-66.
36. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, Justement JS, Stanley S, Fauci AS. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor apha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990; 172: 151-8.
37. Rosenberg AM, Finbloom DS, Maniera TG, Van der Meide PH, Singer A. Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody. J Immunol 1990; 144: 4648-50.
38. Roux-Lombard P, Modoux C, Crushaud A, Dayer G-M. Purified blood monocytes from HIV-1-infected patients produce high levels of TNF-alpha and IL-1. Clin Immunol Immunopathol 1989; 84: 374-84.
39. H2 cytokine secretion phenotype. J Immunol 1994; 153: 3514-22.
40. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with antiinterleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon-gamma-dependent mechanism. J Exp Med 1990; 171: 115-27.
41. Sieling PA, Abrams JS, Yamamura M, Salgame P, Bloom BR, Rea TH, Modlin RL. Immunosuppressive roles for IL-10 and IL-4 in human infection. J Immunol 1993; 150: 5501-10.
42. Skoglund C, Scheynius A, Holmdahl R, Van der Meide PH. Enhancement of DTH reaction and inhibition of class II transplantation antigens by in vivo treatment with antibodies against gamma-interferon. Clin Exp Immunol 1988; 71: 428-32.
43. Solbach W, Moll H, Röllinghoff M. Lymphocytes play the music but the macrophage calls the tune. Immunol Today 1991; 12:4-6.
44. Staruch MJ, Wood DD. Reduction of serum interleukin-1 -like activity after treatment with dexamethasone J Leukocyte Biol 1985; 37: 193-207.
45. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991;5:171-7.
46. Strom TB, Kupiec-Weglinski JW, Heidecke CD, Tilney ML. The cellular and molecular basis of allograft rejection: fact and fancy. Transpl Proc 1985; XVII: 801-5.
47. The IFNB multiple sclerosis study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 655-61.
48. Tracey KJ, Beutler B, Lowry SF, Menyweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ III, Zentella A, Albert JD, Cerami A, Shires GT. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
49. H 1 cells. Immunol Today 1993; 14: 335-7.
50. Uitdehaag BMJ, De Groot CJA, Kreike A, Van der Meide PH, Polman CH, Dijkstra CD. The significance of in-situ la antigen expression in the pathogenesis of autoimmune central nervous system disease. J Autoimmunity 1993; 6: 323-35.
51. Van der Meide PH, Joosten AM, Hermans P, Kloosterman TC, Olsson T, De Labie MCDC. Assessment of the inhibitory effect of immunosuppressive agents on rat T cell interferon-gamma production using an ELISPOT assay. J Immunol Methods 1991; 144: 203-13.
52. Van der Meide PH, De Labie MCDC, Botman CAD, Aten J, Weening JJ. Nitric oxide suppresses IFN-gamma production in the spleen of mercuric chloride-exposed Brown Norway rats. Cell Immunol 1995; 161: 195-206.
53. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355-7.
54. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993; 12: 2663-70.